Clinical trials: Head and Neck Squamous Cell Carcinomas
Squamous Cell Carcinoma of the Oral Cavity, Oropharynx Metastases
A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis
In this study, the feasibility of optical imaging and FDG-PET in the evaluation of radiation-induced mucositis will be evaluated.
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Oropharynx Metastases, Lymph Metastases
- Trial name
- NCT01077869
- Testing
- endoscopic examination, FDG-PET
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Ghent
HNSCC
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
This is a multicenter, open-label, Phase II clinical study to assess the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with recurrent or metastatic HNSCC.
- Trial name
- NCT07668154
- Testing
- SKB571, Pembrolizumab, carboplatin
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma, Adenocarcinoma Of Esophagus
Proton Beam Therapy to Treat Esophageal Cancer
Assess progression-free survival and overall survival of proton beam therapy (PBT) for patients with resectable vs. unresectable esophageal cancer, and to assess patient-reported outcomes of PBT for esophageal cancer at 6 months…
- Trial name
- NCT02023541
- Testing
- Proton beam therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Lymphoepithelioma of the Nasopharynx
Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer
RATIONALE: Transoral robotic surgery (TORS) is a less invasive type of surgery for head and neck cancer and may have fewer side effects and improve recovery.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
- Trial name
- NCT01254734
- Testing
- transoral robotic surgery, laboratory biomarker analysis, quality-of-life assessment
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy (SBRT) in treating participants with head and neck cancer that has spread from where it started to nearby tissue or lymph nodes and…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Trial name
- NCT02388932
- Testing
- Stereotactic Body Radiation Therapy, Positron Emission Tomography, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Case Comprehensive Cancer Center
Oral Squamous Cell Carcinoma
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
Oral cancer is the sixth most common cancer worldwide. Over 90% of all identified oral cavity cancers are invasive oral squamous cell carcinomas (OSCCs).
- Trial name
- NCT03619304
- Testing
- coffee
- Volunteers
- 20 people
- Sponsor
- Cairo University
Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
A Multicenter, Randomized, Controlled, Open-Label, Phase III Clinical Trial.To evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab followed by Benmelstobart in high-risk patients with head and…
- Conditions
- Head & Neck Squamous Cell Carcinoma, Head & Neck Cancer, Postoperative Adjuvant Treatment
- Trial name
- NCT07445048
- Testing
- Bemcentinib, Nimotuzumab, radiotherapy
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
This randomized phase II trial studies how well cetuximab with or without tivantinib works in treating patients with head and neck cancer that has come back (recurrent), has spread to other places in the body (metastatic), or…
- Trial name
- NCT01696955
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Tivantinib
- Where
- 24 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04541355
- Testing
- Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Hyunseok Kang, MD
Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC
This study aims to explore the 2-year DFS (disease-free survival) rate and organ retention rate and to explore the ORR, PCR rate, 2y-OS， and quality of life of patients.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Resection Margin
- Trial name
- NCT05459415
- Testing
- Reducing Excision Margins
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Tests that measure how much saliva is made, hearing, swallowing, voice function, and quality of life may improve the ability to plan treatment for patients with advanced head and neck cancer and may help doctors find…
- Conditions
- Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00415025
- Testing
- adjuvant therapy, management of therapy complications, quality-of-life assessment
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Squamous Cell Carcinoma of the Oropharynx
Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
The investigators are doing this study to learn about the quality of life patients have at the end of treatment. Some patients' cancers are related to human papilloma virus or HPV; others are not.
- Trial name
- NCT01181648
- Testing
- questionnaire and semi-structured interviews
- Where
- 6 sites in United States
- Volunteers
- 210 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Carcinoma
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
This is a single arm phase II study, in which maximum 3 cycles of nivolumab (240 mg fixed dose every 2 weeks) is administered for T2- or T3-node negative esophageal squamous cell carcinoma, before curative operation.
- Trial name
- NCT03987815
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Head and Neck Neoplasms
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
To evaluate the rate of clinical complete response 6-8 weeks after treatment with docetaxel plus cisplatin and 5-fluorouracil followed by chemoradiotherapy and after chemoradiotherapy alone in patients with locally advanced…
- Trial name
- NCT00357149
- Testing
- Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy, Concomitant cisplatin, 5-FU and radiotherapy
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Sanofi
Mouth Neoplasms, Carcinoma, Squamous Cell
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
To confirm the subgroup result from TPF (docetaxel, cisplatin and 5-fluorouracil ) trial (NCT01542931) that cN2 OSCC patients could benefit from TPF induction chemotherapy compared to the standard treatment.
- Trial name
- NCT02285543
- Testing
- TPF induction chemotherapy, surgery, radiotherapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Squamous Cell Carcinoma
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
This study aims to investigate a comprehensive therapeutic approach for patients with unresectable esophageal squamous cell carcinoma, clinically staged as Tany, N3, M0, and who are not candidate for concurrent chemoradiotherapy…
- Trial name
- NCT06122493
- Testing
- Tirelizumab, Nab paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Ruijin Hospital
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT05909904
- Testing
- Tislelizumab, BGB-A425, LBL-007
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 160 people
- Sponsor
- BeiGene
HNSCC
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
To Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.
- Trial name
- NCT04340258
- Testing
- Cesium-131, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Cincinnati
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT04375384
- Testing
- Cetuximab, Questionnaire administration, Quality of life assessment
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
This randomized phase II trial is studying cisplatin and radiation therapy together with or without erlotinib hydrochloride to compare how well they work in treating patients with stage III or stage IV head and neck cancer.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00410826
- Testing
- erlotinib hydrochloride, cisplatin, 3-dimensional conformal radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- University of Washington